Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.
Autor(es): Abdallah Al-Ola,Herlopian Aline,Ravilla Rahul,Bansal Meghana,Chandra-Reddy Sowmya,Mahmoud Fade,Ong Shirley,Gokden Murat,Hutchins Laura
Resumo: Ipilimumab is a novel humanized monoclonal antibody directed against cytotoxic T lymphocyte antigen 4, a T-cell surface molecule involved in down-regulation and suppression of the T cell response to stimuli. Patients treated with ipilimumab are at risk for immune-related adverse events involving the skin, digestive tract, liver and endocrine organs. Few case reports of immune-related adverse effects involving central or peripheral nervous system due to ipilimumab are published. These include inflammatory myopathy, aseptic meningitis, severe meningo-radiculo-neuritis, temporal arteritis, Guillain-Barre syndrome, and posterior reversible encephalopathy syndrome. We report the first case of ipilimumab-induced progressive necrotic myelopathy.
Palavras-Chave: Ipilimumab, immune-related adverse events, progressive necrotic myelopathy
Imprenta: Journal of Oncology Pharmacy Practice, 2015
Identificador do objeto digital: 10.1177/1078155215572932
Descritores: Guillain-Barre Syndrome - Cell ; Guillain-Barre Syndrome - Cytopathology ; Guillain-Barre Syndrome - Immune response
Data de publicação: 2015
